Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab every 2 months versus as-needed dosing for neovascular age-related macular degeneration
2009-017324-11Phase 4Completed
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Jan 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab in age-related macular degeneration (AMD) and Subretinal neovascularization (2 arms), sponsored by Universitätsmedizin Göttingen. Primary endpoint: Change in best-corrected visual acuity at 12 months. Started Jan 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2009-017324-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017324-11.